BioCatalyst

SKB264, Pembrolizumab, Carboplatin, Osimertinib — catalyst calendar

1 verified catalyst event(s) referencing SKB264, Pembrolizumab, Carboplatin, Osimertinib, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-06-30
in 8d
ESTIMATED
 READOUT
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Adva
Phase 2 · Non-small Cell Lung Cancer
 Klus Pharma Inc. SKB264, Pembrolizumab, Carboplatin, Osim ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.